ADVENTRX Pharmaceuticals to Report Results from Phase 2b Clinical Trial of ANX-510 (Cofactor(R))
October 01 2007 - 12:09AM
PR Newswire (US)
Conference call scheduled for October 1, 2007 at 1:00 p.m.
(Eastern); simultaneous webcast at www.adventrx.com SAN DIEGO, Oct.
1 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc.
(AMEX:ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the
treatment of cancer and infectious diseases, today announced that
it will host a conference call and webcast on Monday, October 1st,
2007 to discuss results from its Phase 2b clinical trial of
ANX-510, or CoFactor, for the treatment of metastatic colorectal
cancer. Evan M. Levine, chief executive officer of ADVENTRX, will
host the conference call. The conference call may be accessed by
dialing (800) 665-0430 for domestic callers and (913) 312-0402 for
international callers. The webcast will be available live via the
Internet by accessing ADVENTRX's web site at
http://www.adventrx.com/ under "Investors". Replays of the webcast
will be available for 30 days, and a phone replay will be available
through October 2, 2007 by dialing (888) 203-1112 and entering the
passcode 8640821. About ADVENTRX Pharmaceuticals ADVENTRX
Pharmaceuticals is a biopharmaceutical research and development
company focused on commercializing proprietary product candidates
for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments
by addressing significant problems, such as drug metabolism and
bioavailability, excessive toxicity and treatment resistance. More
information can be found on ADVENTRX's web site at
http://www.adventrx.com/. DATASOURCE: ADVENTRX Pharmaceuticals,
Inc. CONTACT: Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866 Web site: http://www.adventrx.com/
Copyright
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024